Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: DPX-Survivac|DRUG: Letrozole 2.5mg|DRUG: Cyclophosphamide 50mg|RADIATION: XRT 10Gy x2
Sponsor: Providence Health & Services